Pomerantz LLP is investigating claims on behalf of investors of  Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).  Such investors are advised to contact Danielle Peyton ...

Novo Nordisk has struggled to adapt to very high demand and a market where celebrities are more influential than doctors.

That pundit was HSBC's Rajesh Kumar, who downgraded his recommendation on Novo Nordisk that morning. Image source: . Kumar ...

The S&P 500 dropped 0.37% and closed at 6,339.39 for its third straight losing day, while the Nasdaq Composite inched down ...

In the latest trading session, Novo Nordisk (NVO) closed at $47.00, marking a -6.06% move from the previous day. This change lagged the S&P 500's 0.37% loss on the day. Elsewhere, the Dow saw a ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Shares of telehealth company Hims & Hers Health are up Thursday afternoon. The rally comes amid significant headwinds for major pharmaceutical companies in the lucrative weight-loss drug market.

Weight loss drug giant Eli Lilly and Company (NYSE:LLY)’s shares have struggled in 2025 as they have lost 2.3% year-to-date.

Stock futures climbed on Thursday (July 31) after strong quarterly results from tech heavyweights Microsoft and Meta ...

A rally in stocks sputtered ahead of President Donald Trump’s tariff deadline, with the White House demanding drugmakers to ...

Novo Nordisk (NVO) downgraded to Hold by HSBC amid growth concerns, GLP-1 market challenges, and revised 2025-2026 earnings ...

July's jobs report reveals mixed signals. Discover key sectors with growth momentum and risks in labor trends to ...